- Home
- NFJ vs MYGN Comparison
NFJ vs MYGN Comparison
Compare NFJ & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFJ
- MYGN
- Stock Information
- Founded
- NFJ 2005
- MYGN 1991
- Country
- NFJ United States
- MYGN United States
- Employees
- NFJ N/A
- MYGN N/A
- Industry
- NFJ Finance: Consumer Services
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NFJ Finance
- MYGN Health Care
- Exchange
- NFJ Nasdaq
- MYGN Nasdaq
- Market Cap
- NFJ 1.2B
- MYGN 1.3B
- IPO Year
- NFJ N/A
- MYGN 1995
- Fundamental
- Price
- NFJ $12.03
- MYGN $9.94
- Analyst Decision
- NFJ
- MYGN Hold
- Analyst Count
- NFJ 0
- MYGN 15
- Target Price
- NFJ N/A
- MYGN $21.37
- AVG Volume (30 Days)
- NFJ 223.5K
- MYGN 1.3M
- Earning Date
- NFJ 01-01-0001
- MYGN 05-06-2025
- Dividend Yield
- NFJ 9.01%
- MYGN N/A
- EPS Growth
- NFJ N/A
- MYGN N/A
- EPS
- NFJ N/A
- MYGN N/A
- Revenue
- NFJ N/A
- MYGN $837,600,000.00
- Revenue This Year
- NFJ N/A
- MYGN $2.97
- Revenue Next Year
- NFJ N/A
- MYGN $8.37
- P/E Ratio
- NFJ N/A
- MYGN N/A
- Revenue Growth
- NFJ N/A
- MYGN 11.21
- 52 Week Low
- NFJ $10.45
- MYGN $9.36
- 52 Week High
- NFJ $12.86
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- NFJ 31.50
- MYGN 35.24
- Support Level
- NFJ $12.43
- MYGN $9.36
- Resistance Level
- NFJ $12.84
- MYGN $11.44
- Average True Range (ATR)
- NFJ 0.18
- MYGN 0.80
- MACD
- NFJ -0.04
- MYGN -0.12
- Stochastic Oscillator
- NFJ 4.63
- MYGN 16.95
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. Its primary investment objective is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.